An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.
Checked against the public recordLast updated Jan 13, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-02341066
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * histologically or cytologically proven diagnosis of non-small cell lung cancer * positive for the ALK fusion gene (test provided by either a central laboratory. Local laboratory may be used for certain cases) * may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and discontinued treatment due to Response Evaluation Criterion in Solid Tumors (RECIST)-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without RECIST-defined progression. * Tumors can be measurable or non measurable Exclusion Criteria: * prior treatment with PF-02341066 * received no prior systemic treatment, chemotherapy or EGFR tyrosine kinase inhibitor, for advanced non-small cell lung cancer * current enrollment in another therapeutic clinical trial
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama at BirminghamBirmingham, Alabama
- University of Alabama at BirminghamBirmingham, Alabama
- University of Arkansas for Medical SciencesLittle Rock, Arkansas
- Comprehensive Blood and Cancer CenterBakersfield, California
- Tower Cancer Research FoundationBeverly Hills, California
- Tower Hematology Oncology Medical GroupBeverly Hills, California
- Moores UCSD Cancer CenterLa Jolla, California
- UCSD Medical Center - La JollaLa Jolla, California
- Drug Shipping Address: Ronald Reagen University of California-Los AngelesLos Angeles, California
- Ronald Reagen University of California-Los Angeles Medical CenterLos Angeles, California
- UCLA Opthalmic Oncology CenterLos Angeles, California
- University of California-Los AngelesLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 13, 2017. Always confirm current availability with the study team.